Logo (Retacrit 01)
Retacrit Injection, Solution
Product Images NDC 0069-1308
33 FDA label images from Pfizer Laboratories Div Pfizer Inc · Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 33 technical images submitted to the FDA as part of the official labeling for Retacrit (NDC 0069-1308). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Pfizer Laboratories Div Pfizer Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Logo (Retacrit 02)
Figure 1 (Retacrit 03)
An instructional illustration depicting components used for administering an injection: a vial, a disposable syringe with labeled parts (needle cover, plunger rod, syringe barrel with markings), alcohol wipes, a cotton ball, and a puncture-proof container for disposal. The components are clearly labeled and drawn in black and white line art.*
Figure 2 (Retacrit 04)
An instructional diagram showing hands being washed under a faucet with water flowing, illustrating proper hand hygiene technique.*
Figure 3 (Retacrit 05)
An instructional black-and-white line drawing showing a hand holding a small vial or syringe, demonstrating the proper grip or handling technique for an injection device.*
Figure 4 (Retacrit 06)
An instructional illustration showing a hand holding a vial with the other hand removing the vial's cap, likely depicting preparation of an injection. No text or branding is visible in the image.*
Figure 5 (Retacrit 07)
An instructional illustration showing how to remove a syringe cap by pulling it straight off, indicated by a leftward arrow. The image depicts two hands holding a syringe and its cap during the removal process.*
Figure 6 (Retacrit 08)
An instructional line drawing showing two hands preparing a syringe with a vial. One hand holds the vial while the other hand inserts the syringe needle into the vial, demonstrating the process of drawing medication from the vial for injection.*
Figure 7 (Retacrit 09)
An instructional illustration showing a hand inserting a dropper or syringe into a vial, indicated by a downward arrow, likely demonstrating the preparation or drawing up of an injection solution.*
Figure 8 (Retacrit 10)
An instructional line drawing showing hands holding a syringe and vial, depicting the process of withdrawing medication from the vial with the syringe.*
Figure 9 (Retacrit 11)
An instructional line drawing showing a hand holding a syringe with labeled parts: the needle at the top and the plunger at the bottom. The plunger is depicted as being pulled back, illustrating syringe use or preparation steps.*
Figure 10 (Retacrit 12)
An instructional illustration showing hands handling a syringe labeled with 'needle' and 'plunger,' demonstrating proper grip for injection preparation or administration.*
Figure 11 (Retacrit 13)
An instructional diagram showing recommended injection sites on the human body for RETACRIT (epoetin alfa-epbx) injection solution. The front view highlights areas on the abdomen and thighs. The back view shows sites on the upper outer arms, lower back, and buttocks for intravenous and subcutaneous administration.*
Figure 12 (Retacrit 14)
Illustration showing a hand injecting a solution into the upper thigh, demonstrating a subcutaneous injection technique.*
Figure 13 (Retacrit 15)
An instructional illustration showing a hand injecting a solution into the thigh area of a bent leg, likely demonstrating subcutaneous injection technique for RETACRIT (epoetin alfa-epbx) injection.*
Figure 14 (Retacrit 16)
An instructional diagram depicting the correct angles for subcutaneous injection. The image shows a person’s bent knee with a hand pinching the skin, indicating injection angles of 45 degrees and 90 degrees with arrows pointing to the injection site.*
Figure 15 (Retacrit 17)
An illustration showing hands holding or manipulating a small rectangular device or component connected to tubing. The image likely depicts a step in the preparation or administration of an injection solution, such as RETACRIT epoetin alfa-epbx injection.*
Figure 16 (Retacrit 18)
An instructional diagram showing a syringe needle approaching and inserting into the top of a cylindrical vial or cartridge, likely depicting the preparation or withdrawal of RETACRIT injection solution for intravenous or subcutaneous administration.*
Logo (Retacrit 19)
Principal Display Panel (2,000 Units/mL Vial Label)
Label for Retacrit 2000 Units/mL injection, solution, a recombinant epoetin alfa-epbx product. This label identifies a 1 mL single-dose vial from Pfizer Laboratories Division of Pfizer Inc. It includes storage instructions at 2°C to 8°C and notes the dosage information is in the prescribing information. The manufacturing is by Hospira, Inc., a Pfizer company.*
Principal Display Panel (2,000 Units/mL Vial Carton)
Packaging label for Retacrit 2,000 Units/mL injection solution containing epoetin alfa-epbx recombinant. The label indicates a single-dose vial for intravenous or subcutaneous use, with no preservative. The product is manufactured by Pfizer Laboratories Div Pfizer Inc and distributed by Pfizer Labs. The box highlights storage conditions, dosage information, and a barcode.*
Principal Display Panel (3,000 Units/mL Vial Label)
Retacrit 3,000 Units/mL injection, solution label for a 1 mL single-dose vial. The product contains epoetin alfa-epbx recombinant and is manufactured by Hospira, Inc., a Pfizer company. Storage instructions specify 2°C to 8°C. The label includes dosing information directing to see prescribing information and Pfizer Oncology branding.*
Principal Display Panel (3,000 Units/mL Vial Carton)
Retacrit 3,000 Units/mL injection solution carton labeling for epoetin alfa-epbx recombinant by Pfizer Oncology. The label indicates single-dose vials containing 3,000 units per mL, for intravenous or subcutaneous use only. The product is sterile, contains no preservative, and the carton includes standard storage and handling instructions, manufacturer and distributor information, and a phenylalanine warning.*
Principal Display Panel (4,000 Units/mL Vial Label)
Retacrit 4,000 Units/mL injection, solution single-dose vial label. It contains epoetin alfa-epbx recombinant injectable solution. The label includes storage instructions (2°C to 8°C), manufacturer Hospira, Inc. (a Pfizer Company), and distributor Pfizer Labs Division of Pfizer Inc, New York, NY. The vial is indicated for oncology use and is labeled for Rx use only.*
Principal Display Panel (4,000 Units/mL Vial Carton)
Packaging label for RETACRIT 4,000 Units/mL injection solution, epoetin alfa-epbx recombinant, for intravenous or subcutaneous use. Label indicates single-dose vials of 1 mL, sterile solution with no preservative, distributed by Pfizer Labs, division of Pfizer Inc. The label includes storage instructions and ingredients details, as well as the Pfizer Oncology logo.*
Principal Display Panel (10,000 Units/mL Vial Label)
Retacrit 10,000 Units/mL injection, solution label for a 1 mL single-dose vial. The label identifies the product as epoetin alfa-epbx recombinant by Pfizer Oncology. Storage instructions indicate 2°C to 8°C. Dosage directions refer to prescribing information. Manufacturer and distributor details are also shown.*
Principal Display Panel (10,000 Units/mL Vial Carton)
Packaging label for Retacrit 10,000 Units/mL injection, solution containing epoetin alfa-epbx recombinant. The label indicates the product is for intravenous or subcutaneous use only, is a sterile solution with no preservative, and is single-dose. The manufacturer is Pfizer Laboratories Division of Pfizer Inc. Details include storage instructions and a barcode.*
Principal Display Panel (40,000 Units/mL Vial Label)
Retacrit epoetin alfa-epbx recombinant injection, solution, 40,000 Units/mL strength, presented in a 1 mL single-dose vial. Label indicates storage at 2°C to 8°C, prescription-only use, and manufacturer information including Pfizer Laboratories Division, Pfizer Inc, and Hospira Inc. Dosage instructions reference prescribing information.*
Principal Display Panel (40,000 Units/mL Vial Carton)
Packaging label for Retacrit 40,000 Units/mL injection solution, containing epoetin alfa-epbx recombinant. The label specifies use for intravenous or subcutaneous administration and single-dose vials of 1 mL. Distributed by Pfizer Laboratories Division of Pfizer Inc, with storage instructions and formulation details included. The label also features the Pfizer Oncology logo.*
Principal Display Panel (20,000 Units/mL Vial Label)
Label for Retacrit (epoetin alfa-epbx) injection, solution, displaying a strength of 20,000 Units/mL in a 1 mL multiple-dose vial. The label includes storage instructions (2°C to 8°C), dosage directions to refer to prescribing information, and manufacturer details: Hospira, Inc., a Pfizer Company, distributed by Pfizer Labs. A barcode and lot/expiration date area are also present.*
Principal Display Panel (20,000 Units/mL Vial Carton)
Packaging label for Retacrit injection solution, containing epoetin alfa-epbx recombinant at a strength of 20,000 Units/mL. The product is presented in multiple-dose vials (1 mL each) for intravenous or subcutaneous use. Labeler is Pfizer Laboratories Div Pfizer Inc. The label includes usage instructions and storage information.*
Principal Display Panel (20,000 Units/2 mL Vial Label)
Retacrit epoetin alfa-epbx injection solution label for 20,000 Units/2 mL (10,000 Units/mL) multiple-dose vial. The label indicates storage between 2°C to 8°C, dosing per prescribing information, and identifies Pfizer Laboratories as the distributor. The vial is manufactured by Hospira, Inc., a Pfizer company.*
Principal Display Panel (20,000 Units/2 mL Vial Carton)
Retacrit 20,000 Units/2 mL (10,000 Units/mL) injection solution carton label for epoetin alfa-epbx recombinant. The label indicates multiple-dose vials containing 2 mL for intravenous or subcutaneous use. Distributed by Pfizer Laboratories Div Pfizer Inc, it is a sterile, preserved solution. The packaging includes storage instructions, lot number, and bar code details, and emphasizes prescription-only status.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
